COMP <GO>
PPCB vs BDRX // OPERATING MARGIN
Propanc Biopharma Inc. (NASDAQ) VS. Biodexa Pharmaceuticals plc American Depositary Shs (NASDAQ) • 15-METRIC TALLY: PPCB 1
— BDRX 1
■ METRIC PARITY
LAST: $1.84 (-12.80%) • MKT CAP: $2.2M
operating-margins
—
LAST: $3.43 (-12.05%) • MKT CAP: $2.0M
operating-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PPCB VS. BDRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PPCB | BDRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -18.59% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin ACTIVE | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 26.2 | 45.1 | -18.90 | BDRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.2M | $2.0M | $135.3K | PPCB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PPCB REV | BDRX REV | PPCB GROSS % | BDRX GROSS % | PPCB FCF | BDRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | -$405.2K | — |
| FY 2024 | $0 | — | — | — | -$935.1K | — |
| FY 2023 | $0 | — | — | — | -$1.1M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PPCB // BETA —
BDRX // BETA —